




Listing of claims:

1-4. (Cancelled)


5. (Currently Amended) A method of treating a subject who has, or in preventing a subject from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, frontotemporal dementias with parkinsonism (FTDP), dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically effective amount of a compound of formula (I)



wherein Ar is




* indicates a mixture of isomers at this carbon








R_{10} is H or OH;

X is O or an electron pair;

W is




Q is




Z is H or Z and Q taken together are $-(\text{CH}_2)_3-$ or $-(\text{CH}_2)_4-$


U is



R_3 is C_{1-11} -alkyl or




wherein R_{20} is H or C_{1-10} -alkyl; and Ac is formyl or







wherein R_{21} is C_{1-10} -alkyl;

L is



R_2 is




m is 0, 1 or 2;

p is 0, 1 or 2; and

q is 0, 1, or 2;

an epimer or racemate thereof.


6. (Previously Presented) The method according to claim 5, wherein Ar is



7. (Previously Presented) The method according to claim 5, wherein W is selected from the group consisting of $\text{---SO}_2\text{---}$ and ---CO--- .

8. (Previously Presented) The method according to claim 5, wherein W is ---CO--- .

9. (Previously Presented) The method according to claim 5, wherein Q is selected from the group consisting of




10. (Previously Presented) The method according to claim 5, wherein Q is




11. (Previously Presented) The method according to claim 5, wherein Q is




12. (Previously Presented) The method according to claim 5, wherein U is selected from the group consisting of




13. (Previously Presented) The method according to claim 5, wherein U is



14. (Previously Presented) The method according to claim 5, wherein -O-L is




15. (Previously Presented) The method according to claim 5, wherein -O-L is















































16. (Previously Presented) The method according to claim 5, wherein R_2 is selected from the group consisting of NH-tBu or NH-Ph.


17. (Previously Presented) A method according to claim 5, comprising administering a therapeutically effective amount of a compound selected from the group consisting of:




Compound	Ar-W-	Q	U	L
A				

B				
C				
D				
E				
F				
G				
H				
I				


J		 CONH ₂	 NH ₂ (S)	 NH tBu
K		 CONH ₂	 N ₃ (S)	 NH tBu
L		 CONH ₂	 NH ₂ (S)	 NH tBu
M		 CONH ₂	 N ₃ (S)	 NH tBu
N		 CONH ₂	 NH ₂ (S)	 NH tBu
O		 CONH ₂	 N ₃ (S)	 NH tBu
P		 CONH ₂	 NHAc (S)	 NH tBu
Q			 NH ₂ (R)	 NH tBu
R			 N ₃ (R)	 NH tBu
S		 CONH ₂	 N ₃ (R)	 NH tBu
T		 CONH ₂	 NH ₂ (R)	 NH tBu




wherein * denotes all the possible stereoisomers at the particular carbon, and mixtures thereof;



or a mixture thereof;





or pharmaceutically acceptable salts thereof.

18-29. (Canceled)

30. (Previously Presented) A method of treatment according to claim 5, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, P-gp inhibitors, an A beta peptide, and an anti-A beta peptide.

31. (New) A method of treating Alzheimer's disease by modulating the activity of beta amyloid converting enzyme, comprising administering to a subject in need of such treatment a compound disclosed in claim 5, or a pharmaceutically acceptable salt thereof.

32. (New) The method according to claim 5, further comprising the administration of a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.